D-Dimer Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 5.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
D-Dimer Market Analysis
The D-Dimer Market is expected to register a CAGR of 5.1% during the forecast period.
The emergence of COVID-19 led to a slight decline in the D-Dimer market during the initial phases of the pandemic, as there was a lack of availability of tests due to stringent lockdowns and production and manufacturing halts. But during the late stages, the pandemic had a significant impact on the market study as raising D-Dimer values can help identify people who can be at higher risk of COVID-19 complications, including disseminated intravascular coagulation and multi-organ failure. For instance, according to an article published in Dove Press in March 2022, coagulation disorders and acute respiratory failure were the prevailing causes of death from COVID-19. Together with other parameters that constitute the risk profile for severe COVID-19 evolution, the D-Dimers dosing at admission proved to be extremely useful in the management of COVID-19. Furthermore, during the post-pandemic phase, the market has seen a surge due to the rising adoption of D-Dimer, as this act as a biomarker for mortality in COVID-19 patients. For instance, according to another article published in Plos One, the D-Dimer value on admission was an accurate biomarker for predicting mortality in patients with COVID-19. This has led to the rising adoption of D-Dimer testing for the management of COVID-19 disease. Hence, the COVID-19 pandemic had a favorable impact on the market initially. Currently, as the pandemic has subsided, the market has lost some traction. However, it is expected to have stable growth during the forecast period.
A paradigm shift toward the demand for next-generation point-of-care D-Dimer testing has driven the market owing to the implementation of POC solutions significantly reducing waiting time, minimizing the length of patient stay, enabling faster diagnosis, and resulting in improved patient experience. The resounding benefits gained from these solutions in POC settings are considered to boost the growth of the market for D-Dimer testing. A rise in the incidence rate of Venous Thromboembolism (VTE), along with various pulmonary and cardiovascular diseases that cause life-threatening issues due to blood clot formation, is increasing the demand for D-Dimer testing.
According to a study published by the British Heart Foundation in August 2022, there were approximately 7.6 million people with heart and circulatory disease in the United Kingdom. Therefore, due to the high burden of cardiovascular diseases in developed countries such as the United Kingdom, there is an increasing demand for diagnostics assay, which can decrease the mortality rates associated with heart failure, thereby increasing the demand for D-Dimer assay during the study period.
According to an article published in the BMJ in February 2022, the diagnostic strategy using a combination of clinical pretest probability and D-Dimer identified patients at low risk for deep vein thrombosis during follow-up while substantially reducing the need for ultrasound imaging. Therefore, the importance of the D-Dimer test in identifying DVT helps in increased adoption, driving the market growth.
Therefore, owing to the aforementioned factors, the studied market is expected to grow significantly during the study period. However, the stringent regulation and limitations associated with the tests are expected to hinder the market growth during the study period.
D-Dimer Market Trends
This section covers the major market trends shaping the D-Dimer Market according to our research experts:
The Pulmonary Embolism Segment is Expected to Witness a Robust Growth Over the Forecast Period
Pulmonary embolism is a blood coagulation that blocks and stops blood flow to an artery in the lung. The blood clot typically originates in a deep leg vein and goes to the lung.
Growth of the pulmonary embolism segment is attributed to the growing global prevalence of this disease due to a rise in blood plasma D-Dimer levels among women and the rising geriatric population coupled with a higher burden of associated diseases.
The high prevalence of pulmonary embolism in developed countries is expected to drive segment growth during the forecast period. According to the CDC update in June 2022, pulmonary embolism affects up to 900,000 people annually in the United States. Such a huge incidence of pulmonary embolism (PE) is anticipated to drive market growth due to the rising adoption of D-Dimer testing for PE management.
According to another article published in JAMA Network in January 2021, among patients with chronic obstructive pulmonary disease admitted to the hospital with an acute worsening of respiratory symptoms, pulmonary embolism was detected in 5.9% of patients using a predefined diagnostic algorithm. Thus, the high prevalence of pulmonary embolism will fuel the market during the forecast years.
In addition, according to the study published in BMC Pulmonary Medicine in May 2021, in patients with Tuberculous pleural effusion (TPE), D-Dimer is an objective biomarker for predicting PE. Due to its outstanding sensitivity and specificity for PE, a D-Dimer may eliminate pointless radiological examinations. Such advantages of D-Dimer in predicting PE will therefore lead to increased adoption to reduce the harmful radiological examination, propelling the segment growth.
Therefore, the factors such as the versatile advantages of D-Dimer testing in pulmonary embolism and the high prevalence of PE are expected to drive the segment growth.
North America Holds a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a significant share of the D-Dimer market throughout the forecast period. This is due to the rising prevalence of cardiopulmonary disorders and blood disorders such as venous thromboembolism, strokes, and disseminated intravascular coagulation among the huge population of elder individuals, generating higher demand for the D-Dimer test market.
Furthermore, the market in this region is driven due to the factors such as the developed healthcare infrastructure in the United States, the strong foothold of key market players in the region, and rising healthcare expenditure, among others.
As per the CDC update in December 2022, the percentage of coronary heart disease and heart attack for adults aged 18 and over in the United States in 2021 was 4.9% and 3%, respectively. Such a huge prevalence of heart diseases in developed countries will lead to a rise in the adoption of D-Dimer testing for the diagnosis of coronary artery embolism, driving the market growth.
Furthermore, the University of Florida said D-Dimer testing is effective in individuals with COVID-19. This screening blood test, which was validated originally for seriously ill patients without COVID-19, is still useful to rule out pulmonary embolisms (PE) in hospitalized COVID-19 patients. Such research helps in the increased adoption of D-Dimer testing in the region, driving the market growth.
Therefore, factors such as the rising prevalence of cardiopulmonary diseases and rising initiatives from the key market players are expected to drive the market growth over the forecast period.
D-Dimer Industry Overview
The D-Dimer market is moderately competitive and consists of several major players. Few of the key players are entering into partnerships to develop novel methods and test kits, while others are increasing their sales force through partnering with distributors to increase their market position globally. Some of the companies which are currently operating in the market are F. Hoffmann-La Roche Ltd, Abbott Laboratories, Bio-Rad Laboratories Inc., Thermo Fisher Scientific, Danaher Corporation (Beckton Dickinson), BioMerieux, Sysmex Corporation, Henry Schein Inc., and Merck KGaA.
D-Dimer Market Leaders
-
F. Hoffmann-La Roche Ltd
-
Bio-Rad Laboratories Inc
-
Thermo Fisher Scientific
-
Henry Schein, Inc.
-
Bio-Rad Laboratories Inc
*Disclaimer: Major Players sorted in no particular order
D-Dimer Market News
- Jun 2022: LumiraDx expanded its cardiovascular testing portfolio with CE marking of its NT-proBNP test and a new exclusion claim for its D-Dimer test. With its new Exclusion Claim, the LumiraDx D-Dimer test may be used at the point of care (POC) in conjunction with a clinical pre-test probability assessment model to allow clinicians to rule out venous thromboembolism (VTE) in symptomatic patients.
- Mar 2022: SphingoTec and Rivaara Labs entered a distribution agreement for point-of-care diagnostics in India. This agreement includes the distribution of the innovative markers, complemented by commonly used parameters such as procalcitonin, troponin, D-dimer, NT-proBNP, and TSH.
D-Dimer Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Geriatric Population Along with Rise in Disposable Income
- 4.2.2 Rise in Global Prevalence of Cardiopulmonary Disorders such as Stroke and Pulmonary Embolism
-
4.3 Market Restraints
- 4.3.1 Stringent Regulation
- 4.3.2 Limitations Associated with the Tests
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Testing Method
- 5.1.1 Point of Care Testing
- 5.1.2 Laboratory Testing
-
5.2 By Application
- 5.2.1 Deep Vein Thrombosis (DVT)
- 5.2.2 Pulmonary Embolism (PE)
- 5.2.3 Venous Thromboembolism (VTE)
- 5.2.4 Other Applications
-
5.3 By Distribution Channel
- 5.3.1 Diagnostic Laboratories
- 5.3.2 Hospitals
- 5.3.3 Other Distribution Channels
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United states
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle-East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle-East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories
- 6.1.2 Bio-Rad Laboratories Inc.
- 6.1.3 Danaher Corporation (Beckman Coulter)
- 6.1.4 Beckton Dickinson
- 6.1.5 BioMerieux
- 6.1.6 F Hoffmann-La Roche Ltd
- 6.1.7 Siemens Healthineers
- 6.1.8 Sysmex Corporation
- 6.1.9 Merck KGaA
- 6.1.10 Thermo Fisher Scientific
- 6.1.11 Henry Schein Inc.
- 6.1.12 LumiraDx
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityD-Dimer Industry Segmentation
D-Dimer is a fibrin degradation product (FDP) that has two cross-linked D fragments of fibrin formed by the degradation of blood clots, known as fibrinolysis. D-Dimers form in the blood plasma only when the blood coagulation system gets activated due to disseminated intravascular coagulation or thrombosis and thus activates the hemostatic system. The D-Dimer Market is Segmented by Testing Method (Point of Care Testing and Laboratory Testing), Application (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Venous Thromboembolism (VTE), Other Applications), Distribution Channel (Diagnostic Laboratories, Hospitals, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Testing Method | Point of Care Testing | |
| Laboratory Testing | ||
| By Application | Deep Vein Thrombosis (DVT) | |
| Pulmonary Embolism (PE) | ||
| Venous Thromboembolism (VTE) | ||
| Other Applications | ||
| By Distribution Channel | Diagnostic Laboratories | |
| Hospitals | ||
| Other Distribution Channels | ||
| Geography | North America | United states |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
D-Dimer Market Research FAQs
What is the current D-Dimer Market size?
The D-Dimer Market is projected to register a CAGR of 5.10% during the forecast period (2024-2029)
Who are the key players in D-Dimer Market?
F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories Inc, Thermo Fisher Scientific, Henry Schein, Inc. and Bio-Rad Laboratories Inc are the major companies operating in the D-Dimer Market.
Which is the fastest growing region in D-Dimer Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in D-Dimer Market?
In 2024, the North America accounts for the largest market share in D-Dimer Market.
What years does this D-Dimer Market cover?
The report covers the D-Dimer Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the D-Dimer Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
D-Dimer Industry Report
Statistics for the 2024 D-Dimer market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. D-Dimer analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
